Immune classification of colorectal cancer patients: impressive but how complete?

Bibliography

• Rahir G, Moser M. Tumor microenvironment and lymphocyte infiltration. Cancer Immunol Immunother 2012;61(6):751-9
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313(5795):1960-4
   PubMed Web of Science ®Google Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D, Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348(3):203-13
   PubMed Web of Science ®Google Scholar
• Denkert C, Loibl S, Noske A, Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010;28(1):105-13
   PubMed Web of Science ®Google Scholar
• Hornychova H, Melichar B, Tomsova M, Tumor-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma. Cancer Invest 2008;26(10):1024-31
   PubMed Web of Science ®Google Scholar
• Al-Shibli KI, Donnem T, Al-Saad S, Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 2008;14(16):5220-7
   PubMed Web of Science ®Google Scholar
• Marrogi AJ, Munshi A, Merogi AJ, Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma. Int J Cancer 1997;74(5):492-501
   PubMed Web of Science ®Google Scholar
• Kusmartsev S, Gabrilovich DI. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother 2006;55(3):237-45
   PubMed Web of Science ®Google Scholar
• Whiteside TL. Disarming suppressor cells to improve immunotherapy. Cancer Immunol Immunother 2012;61(2):283-8
   PubMed Web of Science ®Google Scholar
• Wilke CM, Kryczek I, Wei S, Th17 cells in cancer: help or hindrance? Carcinogenesis 2011;32(5):643-9
   PubMed Web of Science ®Google Scholar
• Strauss L, Bergmann C, Szczepanski M, A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res 2007;13(15 Pt 1):4345-54
   PubMed Web of Science ®Google Scholar
• Zou W, Restifo NP. T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 2010;10(4):248-56
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008;133(5):775-87
   PubMed Web of Science ®Google Scholar
• Sato T, Terai M, Tamura Y, Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunol Res 2011;51(2-3):170-82
   PubMed Web of Science ®Google Scholar
• Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006;116(7):1935-45
   PubMed Web of Science ®Google Scholar
• Gritzapis AD, Voutsas IF, Lekka E, Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells. Cancer Res 2010;70(7):2686-96
   PubMed Web of Science ®Google Scholar
• Mahalingam J, Lin YC, Chiang JM, LAP+CD4+ T Cells Are Suppressors Accumulated in the Tumor Sites and Associated with the Progression of Colorectal Cancer. Clin Cancer Res 2012;18(19):5224-33
   PubMed Web of Science ®Google Scholar
• Emmerich J, Mumm JB, Chan IH, IL-10 directly activates and expands tumor-resident CD8(+) T cells without de novo infiltration from secondary lymphoid organs. Cancer Res 2012;72(14):3570-81
   PubMed Web of Science ®Google Scholar
• Kryczek I, Wei S, Szeliga W, Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 2009;114(2):357-9
   PubMed Web of Science ®Google Scholar
• Nam JS, Terabe M, Kang MJ, Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res 2008;68(10):3915-23
   PubMed Web of Science ®Google Scholar
• Higgins CA, Hatton WJ, McKerr G, Macrophages and apoptotic cells in human colorectal tumours. Biologicals 1996;24(4):329-32
   PubMed Web of Science ®Google Scholar
• Hung K, Hayashi R, Lafond-Walker A, The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998;188(12):2357-68
   PubMed Web of Science ®Google Scholar
• Klintrup K, Makinen JM, Kauppila S, Inflammation and prognosis in colorectal cancer. Eur J Cancer 2005;41(17):2645-54
   PubMed Web of Science ®Google Scholar
• George S, Primrose J, Talbot R, Will Rogers revisited: prospective observational study of survival of 3592 patients with colorectal cancer according to number of nodes examined by pathologists. Br J Cancer 2006;95(7):841-7
   PubMed Web of Science ®Google Scholar
• Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst 2007;99(6):433-41
   PubMed Web of Science ®Google Scholar
• Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23(3):609-18
   PubMed Web of Science ®Google Scholar
• Ogino S, Nosho K, Kirkner GJ, CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009;58(1):90-6
   PubMed Web of Science ®Google Scholar
• Ogino S, Nosho K, Irahara N, Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res 2009;15(20):6412-20
   PubMed Web of Science ®Google Scholar
• Roxburgh CS, Salmond JM, Horgan PG, Comparison of the prognostic value of inflammation-based pathologic and biochemical criteria in patients undergoing potentially curative resection for colorectal cancer. Ann Surg 2009;249(5):788-93
   PubMed Web of Science ®Google Scholar
• Huh JW, Lee JH, Kim HR. Prognostic significance of tumor-infiltrating lymphocytes for patients with colorectal cancer. Arch Surg 2012;147(4):366-72
   PubMed Web of Science ®Google Scholar
• Guidoboni M, Gafa R, Viel A, Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. Am J Pathol 2001;159(1):297-304
   PubMed Web of Science ®Google Scholar
• Zlobec I, Terracciano LM, Lugli A. Local recurrence in mismatch repair-proficient colon cancer predicted by an infiltrative tumor border and lack of CD8+ tumor-infiltrating lymphocytes. Clin Cancer Res 2008;14(12):3792-7
   PubMed Web of Science ®Google Scholar
• Prall F, Duhrkop T, Weirich V, Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol 2004;35(7):808-16
   PubMed Web of Science ®Google Scholar
• Morris M, Platell C, Iacopetta B. Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy. Clin Cancer Res 2008;14(5):1413-17
   PubMed Web of Science ®Google Scholar
• Pages F, Berger A, Camus M, Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005;353(25):2654-66
   PubMed Web of Science ®Google Scholar
• Salama P, Phillips M, Grieu F, Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009;27(2):186-92
   PubMed Web of Science ®Google Scholar
• Tosolini M, Kirilovsky A, Mlecnik B, Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, Th2, Treg, Th17) in patients with colorectal cancer. Cancer Res 2011;71(4):1263-71
   PubMed Web of Science ®Google Scholar
• Levy EM, Roberti MP, Mordoh J. Natural killer cells in human cancer: from biological functions to clinical applications. J Biomed Biotechnol 2011;2011:676198
   PubMedGoogle Scholar
• Gulubova M, Manolova I, Kyurkchiev D, Decrease in intrahepatic CD56+ lymphocytes in gastric and colorectal cancer patients with liver metastases. Apmis 2009;117(12):870-9
   PubMed Web of Science ®Google Scholar
• Halama N, Braun M, Kahlert C, Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin Cancer Res 2011;17(4):678-89
   PubMed Web of Science ®Google Scholar
• Menon AG, Janssen-van Rhijn CM, Morreau H, Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab Invest 2004;84(4):493-501
   PubMed Web of Science ®Google Scholar
• Kondo T, Takata H, Matsuki F, Takiguchi M. Cutting edge: phenotypic characterization and differentiation of human CD8+ T cells producing IL-17. J Immunol 2009;182(4):1794-8
   PubMed Web of Science ®Google Scholar
• Intlekofer AM, Banerjee A, Takemoto N, Anomalous type 17 response to viral infection by CD8+ T cells lacking T-bet and eomesodermin. Science 2008;321(5887):408-11
   PubMed Web of Science ®Google Scholar
• Tajima M, Wakita D, Noguchi D, IL-6-dependent spontaneous proliferation is required for the induction of colitogenic IL-17-producing CD8+ T cells. J Exp Med 2008;205(5):1019-27
   PubMed Web of Science ®Google Scholar
• Weaver CT, Hatton RD. Interplay between the TH17 and TReg cell lineages: a (co-)evolutionary perspective. Nat Rev Immunol 2009;9(12):883-9
   PubMed Web of Science ®Google Scholar
• Dubin PJ, Kolls JK. Th17 cytokines and mucosal immunity. Immunol Rev 2008;226:160-71
   PubMed Web of Science ®Google Scholar
• Beriou G, Costantino CM, Ashley CW, IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood 2009;113(18):4240-9
   PubMed Web of Science ®Google Scholar
• Voo KS, Wang YH, Santori FR, Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc Natl Acad Sci USA 2009;106(12):4793-8
   PubMed Web of Science ®Google Scholar
• Huang C, Fu ZX. Localization of IL-17+Foxp3+ T cells in esophageal cancer. Immunol Invest 2011;40(4):400-12
   PubMed Web of Science ®Google Scholar
• Kryczek I, Banerjee M, Cheng P, Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009;114(6):1141-9
   PubMed Web of Science ®Google Scholar
• Sfanos KS, Bruno TC, Maris CH, Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res 2008;14(11):3254-61
   PubMed Web of Science ®Google Scholar
• Koyama K, Kagamu H, Miura S, Reciprocal CD4+ T-cell balance of effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ regulatory T cells in small cell lung cancer reflects disease stage. Clin Cancer Res 2008;14(21):6770-9
   PubMed Web of Science ®Google Scholar
• Muranski P, Boni A, Antony PA, Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008;112(2):362-73
   PubMed Web of Science ®Google Scholar
• Kottke T, Sanchez-Perez L, Diaz RM, Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer. Cancer Res 2007;67(24):11970-9
   PubMed Web of Science ®Google Scholar
• Gnerlich JL, Mitchem JB, Weir JS, Induction of Th17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer. J Immunol 2010;185(7):4063-71
   PubMed Web of Science ®Google Scholar
• Numasaki M, Watanabe M, Suzuki T, IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 2005;175(9):6177-89
   PubMed Web of Science ®Google Scholar
• Numasaki M, Fukushi J, Ono M, Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003;101(7):2620-7
   PubMed Web of Science ®Google Scholar
• Wang L, Yi T, Kortylewski M, IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 2009;206(7):1457-64
   PubMed Web of Science ®Google Scholar
• Derhovanessian E, Adams V, Hahnel K, Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int J Cancer 2009;125(6):1372-9
   PubMed Web of Science ®Google Scholar
• Zhang B, Rong G, Wei H, The prevalence of Th17 cells in patients with gastric cancer. Biochem Biophys Res Commun 2008;374(3):533-7
   PubMed Web of Science ®Google Scholar
• Zhang YL, Li J, Mo HY, Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways. Mol Cancer 2010;9:4
   PubMed Web of Science ®Google Scholar
• Ye ZJ, Zhou Q, Gu YY, Generation and differentiation of IL-17-producing CD4+ T cells in malignant pleural effusion. J Immunol 2010;185(10):6348-54
   PubMed Web of Science ®Google Scholar
• Zhou X, Bailey-Bucktrout S, Jeker LT, Bluestone JA. Plasticity of CD4(+) FoxP3(+) T cells. Curr Opin Immunol 2009;21(3):281-5
   PubMed Web of Science ®Google Scholar
• Pan F, Yu H, Dang EV, Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells. Science 2009;325(5944):1142-6
   PubMed Web of Science ®Google Scholar
• Bettelli E, Dastrange M, Oukka M. Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells. Proc Natl Acad Sci USA 2005;102(14):5138-43
   PubMed Web of Science ®Google Scholar
• Ono M, Yaguchi H, Ohkura N, Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature 2007;446(7136):685-9
   PubMed Web of Science ®Google Scholar
• Zhou L, Lopes JE, Chong MM, TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 2008;453(7192):236-40
   PubMed Web of Science ®Google Scholar
• Mantel PY, Kuipers H, Boyman O, GATA3-driven Th2 responses inhibit TGF-beta1-induced FOXP3 expression and the formation of regulatory T cells. PLoS Biol 2007;5(12):e329
   PubMed Web of Science ®Google Scholar
• Huang B, Pan PY, Li Q, Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006;66(2):1123-31
   PubMed Web of Science ®Google Scholar
• Pan PY, Ma G, Weber KJ, Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res 2010;70(1):99-108
   PubMed Web of Science ®Google Scholar
• Mandapathil M, Hilldorfer B, Szczepanski MJ, Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J Biol Chem 2010;285(10):7176-86
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L, Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10(9):942-9
   PubMed Web of Science ®Google Scholar
• Wolf D, Wolf AM, Rumpold H, The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 2005;11(23):8326-31
   PubMed Web of Science ®Google Scholar
• Bates GJ, Fox SB, Han C, Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006;24(34):5373-80
   PubMed Web of Science ®Google Scholar
• deLeeuw RJ, Kost SE, Kakal JA, Nelson BH. The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res 2012;18(11):3022-9
   PubMed Web of Science ®Google Scholar
• Milne K, Kobel M, Kalloger SE, Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One 2009;4(7):e6412
   PubMed Web of Science ®Google Scholar
• Correale P, Rotundo MS, Del Vecchio MT, Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J Immunother 2010;33(4):435-41
   PubMed Web of Science ®Google Scholar
• Haas M, Dimmler A, Hohenberger W, Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia. BMC Gastroenterol 2009;9:65
   PubMed Web of Science ®Google Scholar
• Ladoire S, Martin F, Ghiringhelli F. Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol Immunother 2011;60(7):909-18
   PubMed Web of Science ®Google Scholar
• Whiteside TL. Immune responses to malignancies. J Allergy Clin Immunol 2010;125(2 Suppl 2):S272-83
   PubMed Web of Science ®Google Scholar
• Winerdal ME, Marits P, Winerdal M, FOXP3 and survival in urinary bladder cancer. BJU Int 2011;108(10):1672-8
   PubMed Web of Science ®Google Scholar
• Shah W, Yan X, Jing L, A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4(+)FOXP3(+) regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix. Cell Mol Immunol 2011;8(1):59-66
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Katou F, Ohtani H, Tumor-infiltrating lymphocytes, particularly the balance between CD8(+) T cells and CCR4(+) regulatory T cells, affect the survival of patients with oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;109(5):744-52
   PubMed Web of Science ®Google Scholar
• Iliopoulou EG, Karamouzis MV, Missitzis I, Increased frequency of CD4+ cells expressing CD161 in cancer patients. Clin Cancer Res 2006;12(23):6901-9
   PubMed Web of Science ®Google Scholar
• Solstad T, Bains SJ, Landskron J, CD147 (Basigin/Emmprin) identifies FoxP3+CD45RO+CTLA4+-activated human regulatory T cells. Blood 2011;118(19):5141-51
   PubMed Web of Science ®Google Scholar
• Goldstein MJ, Kohrt HE, Houot R, Adoptive cell therapy for lymphoma with CD4 T cells depleted of CD137-expressing regulatory T cells. Cancer Res 2012;72(5):1239-47
   PubMed Web of Science ®Google Scholar
• Smith SE, Hoelzinger DB, Dominguez AL, Signals through 4-1BB inhibit T regulatory cells by blocking IL-9 production enhancing antitumor responses. Cancer Immunol Immunother 2011;60(12):1775-87
   PubMed Web of Science ®Google Scholar
• Purwar R, Schlapbach C, Xiao S, Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med 2012
   PubMed Web of Science ®Google Scholar
• Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012;12(4):237-51
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008;8(1):59-73
   PubMed Web of Science ®Google Scholar
• Whiteside TL. Down-regulation of zeta-chain expression in T cells: a biomarker of prognosis in cancer? Cancer Immunol Immunother 2004;53(10):865-78
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012;12(4):298-306
   PubMed Web of Science ®Google Scholar
• Cipponi A, Wieers G, van Baren N, Coulie PG. Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why? Cancer Immunol Immunother 2011;60(8):1153-60
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711-23
   PubMed Web of Science ®Google Scholar